Long-term outcomes of combination photodynamic therapy with ranibizumab or bevacizumab for treatment of wet age-related macular degeneration

Oman Journal of Ophthalmology

Volumn 9, Issue 2, 2016, Pages 87-92

  Rishi, Ekta ^a   Rishi, Pukhraj ^a   Sharma, Vishal ^a   Koundanya, Vikram ^a   Athanikar, Renu ^a  

^a SANKARA NETHRALAYA   (India)

Author keywords

Age related macular degeneration; Bevacizumab; Choroidal neovascularization; Combination therapy; Photodynamic therapy; Ranibizumab

Indexed keywords

EID: 84977658899     PISSN: 0974620X     EISSN: 09747842     Source Type: Journal    
DOI: 10.4103/0974-620X.184511     Document Type: Article

References (19)

1. Klein R, Klein BE, Tomany SC, Meuer SM, Huang GH. Ten-year incidence and progression of age-related maculopathy: The Beaver Dam eye study. Ophthalmology 2002;109:1767-79
2. Nirmalan PK, Katz J, Robin AL, Tielsch JM, Namperumalsamy P, Kim R, et al. Prevalence of vitreoretinal disorders in a rural population of southern India: The Aravind Comprehensive Eye Study. Arch Ophthalmol 2004;122:581-6
3. Azad R, Chandra P, Gupta R. The economic implications of the use of anti-vascular endothelial growth factor drugs in age-related macular degeneration. Indian J Ophthalmol 2007;55:441-3
4. Kaiser PK, Boyer DS, Cruess AF, Slakter JS, Pilz S, Weisberger A; DENALI Study Group. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month results of the DENALI study. Ophthalmology 2012;119:1001-10
5. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355:1419-31
6. Brown DM, Michels M, Kaiser PK, Heier JS, Sy JP, Ianchulev T; ANCHOR Study Group. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study. Ophthalmology 2009;116:57-65.e5
7. IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, et al. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-411
8. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, et al. Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results. Ophthalmology 2012;119:1388-98
9. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: One-year results of 2 randomized clinical trials - TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group. Arch Ophthalmol 1999;117:1329-45
10. Kaiser PK; Visudyne in Occult CNV (VIO) Study Group. Verteporfin PDT for subfoveal occult CNV in AMD: Two-year results of a randomized trial. Curr Med Res Opin 2009;25:1853-60
11. Lazic R, Gabric N. Verteporfin therapy and intravitreal bevacizumab combined and alone in choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2007;114:1179-85
12. Larsen M, Schmidt-Erfurth U, Lanzetta P, Wolf S, Simader C, Tokaji E, et al. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: Twelve-month MONT BLANC study results. Ophthalmology 2012;119:992-1000
13. Abraham P, Yue H, Wilson L. Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 2. Am J Ophthalmol 2010;150:315-24.e1
14. Schmidt-Erfurth U, Eldem B, Guymer R, Korobelnik JF, Schlingemann RO, Axer-Siegel R, et al. Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: The EXCITE study. Ophthalmology 2011;118:831-9
15. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: Year 2 of the PrONTO Study. Am J Ophthalmol 2009;148:43-58.e1
16. Patel PJ, Tufail A; for the ABC Trial Investigators. Optimizing individualized therapy with bevacizumab for neovascular age-related macular degeneration. Retina 2012; doi: 10.1097/IAE.0b013e31823f0ba3. [Epub ahead of print]
17. Heier JS, Boyer DS, Ciulla TA, Ferrone PJ, Jumper JM, Gentile RC, et al. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: Year 1 results of the FOCUS Study. Arch Ophthalmol 2006;124:1532-42
18. Datseris I, Kontadakis GA, Diamanti R, Datseris I, Pallikaris IG, Theodossiadis P, et al. Prospective comparison of low-fluence photodynamic therapy combined with intravitreal bevacizumab versus bevacizumab monotherapy for choroidal neovascularization in age-related macular degeneration. Semin Ophthalmol 2015;30:112-7
19. Spielberg L, Leys A. Treatment of neovascular age-related macular degeneration with a variable ranibizumab dosing regimen and one-time reduced-fluence photodynamic therapy: The TORPEDO trial at 2 years. Graefes Arch Clin Exp Ophthalmol 2010;248:943-56